Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

By A. Younes, A. Gopal, Scott E. Smith, S. Ansell, J. Rosenblatt, K. Savage, R. Ramchandren, N. Bartlett, B. Cheson, S. de Vos and 8 more. Journal of Clinical Oncology, 2012

1,465 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2069469c59406f96a062bc82618940a0863f4ddd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Shi
2. Shijun Li
3. Zhiwen Fu
4. Yu Zhang
5. Sifei Han

Citations in the corpus

• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. (2017, neutral): “(%) 4 (2-12) 4 (1-11) 3 (2-10) 4 (1-12) Prior lines of therapy, No.”
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “The AEs ≥ grade 3 occurring in ≥ 5% of patients were neutropenia (20%), peripheral sensory neuropathy (8%), thrombocytopenia (8%), and anemia (6%).(160) While for sALCL, it was evaluated in a phase II, single-arm, multicenter study in 58 patients with r/r sALCL.”
• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018, neutral): “Median age, years (IQR) 33 (26-45) 37 (28-48) 32 (25-47) 34 (26-46) $ 60 5 (8) 7 (9) 3 (3) 15 (6) Male 34 (54) 51 (64) 56 (56) 141 (58) ECOG PS 0 39 (62) 42 (53) 50 (50) 131 (54) 1 24 (38) 38 (48) 50 (50) 112 (46) Disease stage at study entry I 1 (2) 1 (1) 2 (2) 4 (2) II 20 (32) 11 (14) 20 (20) 51 (”